Partners Innovation Fund joined Syncona to provide $20m for the neurological disease drug developer's series A round, which is sized at up to $77m.
US-based gene therapy developer SwanBio Therapeutics extended a series A round featuring Partners Innovation Fund (PIF), the corporate venture capital vehicle formed by health system Partners HealthCare, to $77m yesterday.
PIF and life sciences company builder and investment firm Syncona committed a further $52m to the round, which came after it invested $23m to lead the round’s $25m first tranche in June 2018, with PIF supplying the rest.
Syncona has provided a further $19.6m for the round and PIF $400,000.…
